Next, we co-cultured TIL alone, with CD5+CD19+ B cells, or with CD5+CD19+ B cells treated with W6/32 antibody to block MHC class I, and the results revealed no TIL reactivity to CLL (Supplementary Figure 2). The gene discussed is CD19; the disease is B-cell chronic lymphocytic leukemia.